EP-1412: Experience using a commercial software for patient in-vivo and pre-treatment quality assurance  by Reversi, L. et al.
S762                                                                                                                                         3rd ESTRO Forum 2015 
 
C. Bhatt1, K. Chufal1, M. Semwal2, K. Sharma3, S. Kumar1, N. 
Kumar1 
1Batra Hospital & Medical Research Center, Radiation 
Oncology Department, Delhi, India  
2Army Hospital (R and R), Radiation Oncology Department, 
New Delhi, India  
3Graphic Era University, Allied Science, Dehradun, India  
 
Purpose/Objective: We propose a Quality Assurance (QA) 
procedure for a Volumatric Intensity Modulated Arc Therapy 
(VMAT) delivery technique namely Rapid Arc by dividing a 
complete arc into sub arc plans and verify fluence using the 
amorphous silicon electronic portal imaging device (a-Si EPID) 
for measurements. 
Materials and Methods: The introduction of advanced 
irradiation techniques in a radiotherapy clinic requires 
extensive dose verification measures that go beyond current 
routine clinical practice. Rapid Arc is a VMAT technology 
developed by M/s Varian medical Systems. A Rapid Arc (RA) 
treatment plan is made possible by a treatment planning 
algorithm that simultaneously changes three parameters 
during treatment, i) rotation speed of the gantry ii) shape of 
the treatment aperture using the movement of multileaf 
collimator leaves, and iii) delivery dose rate. Due to the 
complexity of treatment planning and delivery there is a 
necessity of dosimetric verification of a RapidArc plan. 
Generally, this verification is carried out using ion chambers, 
diodes, films, 2D array & other tools which is cumulative in 
nature and also time consuming. In this study we created a 
RapidArc QA plan using Eclipse-10 (Varian medical Systems) 
treatment planning system and carried out the dosimetry 
with an amorphous silicon electronic portal imaging device 
(a-Si EPID). The RA delivers a precisely sculpted 3D dose 
distribution with 360-degree rotation of the linear 
accelerator gantry, and hence the conventional cumulative 
dosimetry based QA tools may miss instant deviations from 
the planned delivery at specific gantry angles or control 
points. To overcome this problem, we divided a counter 
clockwise (CCW) and clockwise (CW) Rapid Arc of 358' 
delivery into 7 small sub arcs of 50´ each in Eclipse 
treatment planning system, and measured these sub arcs 
using amorphous silicon electronic portal imaging device (a-Si 
EPID). We analysed these sub arcs and composite arc EPID 
dose fluence using the portal dosimetry software. We also 
analysed the cumulative dose image generated by summation 
of all sub arcs. A total of 20 Rapid Arc Patient planning were 
analysed for this study. 
Results: The gamma index (DTA: 3.0 mm Tolerance: 3.0 %) 
evaluated by us indicated good correlation between 
predicted and acquired EPID images for a complete arc with a 
few differences in high gradient areas. In the case of sub arc 
QA, it was found that gamma index was violated in a two 
patients with one sub Arc for Area Gamma < 1.0 is 65.3% and 
88.9 %, where tolerance is 95.0 %. Interestingly, for these 
patients the cumulative QA results showed no violation. 
Conclusions: It is, therefore, concluded that QA of RA plans 
based on sub arcs methods should be part of the overall QA 
process. Specially for complex treatment plan where we are 
trying to save critical organ vary close proximity of target 
using Rapid Arc. So we found the a-Si EPID -based pre-
treatment RA verification method to be a good quality 
assurance (QA) procedure for the purpose. 
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Purpose/Objective: The aim of this study is to test the 
accuracy of the dose calculation algorithm available in 
DosimetryCheck (DC, MathResolution®), a patient QA 
software. 
Materials and Methods: DC allows for both pre-treatment QA 
and in vivo dose verification, using the EPID measured 
fluence of the treatment fields to reconstruct the dose 
distribution in the CT planning model of the patient. First 
tests were performed on the IBA 'I'm RT' phantom to assess 
DC performances in the steps of entrance fluence estimation 
and dose calculation. The central cubic insert was filled in 
three different ways: homogeneously with RW3 slabs 
(phantom H) or replacing the central slabs with air (phantom 
A) or bone inserts (phantom B). The accuracy of entrance 
fluence estimation independently of the irradiated object 
was evaluated acquiring EPID data in vivo and pre treatment 
on the three phantoms for different square field sizes (FS) 
and then evaluating the isocenter dose in phantom H with 
DC. The global accuracy was assessed by comparing OFs and 
PDDs evaluated with TPS with that reconstructed by DC. 
Finally, DC was run on pre-treatment and in-vivo images of 15 
patients: 1) 7 IMRT prostate cases, 2) 3 abdominal VMAT 
cases, 3) 5 head VMAT cases. Gamma analysis (3%, 3mm) was 
used to compare measured with calculated dose distribution.  
Results: Average absolute differences of isocenter doses in 
phantom H obtained with DC from in vivo measurement with 
respect to that obtained from pre treatment measurement 
were 0.43%, 0.82% and 0.92% for B, H and A phantoms 
respectively. Maximum deviation (1.75%) was observed for 
phantom A and 3.2 cm FS. Pre treatment measurements 
produced relative differences on OFs between 0.01/0.53%. H 
and B phantoms gave similar values (-0.48/0.92%, and 
0.70/0.80% respectively). Due to the use of a pencil beam 
algorithm (PB), higher differences were found in phantom A, 
especially for small fields (64.2% for 2.4 cm FS vs -2.1% for 
15.2 cm FS). The effects of the PB were also observed on the 
PDDs. For H and B phantoms, the percent difference 
remained within 1/1.5% at all depths (exception for the 
buildup region) for the 3.2 and 10.4 cm FSs respectively. For 
the A phantom, DC overestimated the dose up to 12% and 
110% in the air thickness for the 10.4 cm and 2.4 cm field 
size respectively. Patients results are summarised in table 
1.For each patient the value of the dose difference at the 
isocenter, PTV and patient gamma passing rates are 
reported. The in vivo values are the average values of the 
treatment sessions acquired. The worst result has been 
obtained for PTV pre and in vivo head treatment where the 
DC algorithm fails due to air in the nasal cavity.  
 




Conclusions: DC is capable of successfully reconstruct the 
dose distribution in the patient from the EPID measured exit 
fluences. In our experience, systematic in vivo dosimetry 
demonstrated to be a valid tool for quality assurance, both in 
detecting systematic errors and in giving an effective way of 
estimating the accuracy of treatment delivery.  
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Purpose/Objective: After introducing IMRT technique, 
several studies showed that 6MV should be first choice of 
energy. However, our clinical practice and some research 
made on prostate cancer plans, shows that mixing energies 
plans allow to use advantages of higher energy with 
minimizing negative impact at the same time. Pre-treatment 
verification of mixed-energy plans seems to be more 
complicated because splitting these plans to two single 
energies plans gives two sets of data for separate evaluation 
with adequate calibration. The purpose of this work was to 
test quite an easy way of evaluating mixed-energy IMRT pre–
treatment verification plans. Octavius 4D system for 
measurements and Verisoft (PTW) for evaluation were used. 
Materials and Methods: For 35 patients, with different 
cancer location, mixed-energy IMRT (6MV and 15MV) plans 
have been prepared. RT plans were prepared on Eclipse TPS 
with sliding window technique. For each plan, three pre-
treatment verification plans were: one plan with all beams, 
and two separate plans for each photon energy beam. 
Verification plans were evaluated for separate energies at 
first. Than, after 3D dose calculation, measurements were 
exported into dicom files. Mixed-energy verification plan was 
compared with sum of RT dose dicom files for separate 
energies (summed plan). Each comparison was done with 
gamma 3D concept for different set of parameters: 
a) 3mm 3% of max dose (33max) 
b) 3mm 3% of local dose (33local) 
Each time dose below 10% of max dose calculated volume 
was suppressed and increased toleration of 5% dose 
difference for values below 0.5Gy was used. Weighted 
average gamma result for separate energies verification plans 
were calculated, where number of fields with each energy 
served as weight. Result of gamma 3D evaluation for summed 
plan and weighted average result were compared. Wilcoxon 
signed-rank test was used. 
Results: In Figure 1 you can see results of gamma evaluation 
with 33max and 33local criteria for separate energies, 
summed plans and weighted average for separate energies as 
well. Wilcoxon signed-rank test confirmed null hyphotesis of 
no significant differences between gamma results weighted 
average for single energy plans and summed plans (p-values 
were: 0.92 for 33max; 0.63 for 33local). 
 
 
Figure 1. Comparison of results of gamma evaluation with 
33max and 33local criteria for separate energies, summed 
plans and weighted average for separate energies 
 
 
Conclusions: Proposed by us method of summing up dicom RT 
dose files for single-energy plans is easy to use and gives one 
single result of gamma comparison, which is quite easy to 
interpret. Although there is no significant difference for 
33max, 33local we highly recommend to use gamma 
evaluation for summed plans. 
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Purpose/Objective: MLC transmision (MLCT) and dosimetric 
leaf gap (DLG) in Treatment Planning System (TPS) are 
